

NaDeNo Nanoscience AS selected for EIC Accelerator grant – awarded up to €10 million financing

Oslo/Trondheim – February 18, 2026 – NaDeNo Nanoscience AS (“NaDeNo”), a biotechnology company pioneering an innovative nanoparticle-based drug delivery platform, has been selected for EIC Accelerator funding. The financing will advance NaDeNo’s lead candidate PACAB-002 through clinical Phase 1 in patients with ovarian cancer and support continued development and expansion of the company’s platform technology.

Through this award, NaDeNo will be supported with a €2.5 million non-dilutive grant from the European Innovation Council (EIC), together with up to €7.5 million in equity matching from the venture investment arm of the EIC. The EIC Accelerator program is widely recognized as one of Europe’s most selective and competitive funding initiatives, backing up start-ups and SMEs with truly disruptive technologies and high-impact innovation potential. In this round, NaDeNo was chosen as one of 61 companies from a total application pool of 923 in a comprehensive evaluation process.

“We are honored to receive this prestigious external validation of our technology, clinical strategy and team from the EIC Accelerator. The funding will take NaDeNo through the first clinical trial and enable the advancement of new candidates from our drug delivery platform towards clinical development” says Annbjørg Falck, CEO and Co-founder of NaDeNo.

“The EIC Accelerator funding allows us to take PACAB-002 through Phase 1, which represents a critical value inflection point for the program. Beyond enabling the clinical trial itself, the support positions NaDeNo as a Phase 2 ready company, with the capabilities, data and organizational maturity required for the next stage of clinical development,” says Jens Bjørheim, Chief Medical Officer at NaDeNo.

About NaDeNo

NaDeNo is a Norwegian biotechnology company focused on developing nanotechnology-based solutions for cancer treatment. The lead candidate, PACAB-002, is a novel nanoparticle-based formulation of the chemotherapeutic agent cabazitaxel, designed for local treatment. PACAB-002 is intended for ovarian cancer patients who are in complete response following standard therapy but remain at high risk of relapse due to microscopic residual disease in the peritoneal cavity.

For more information please visit:

Full press release from the European Innovation Council ([LINK](#)).

Company website: <https://naden.com/>

Contact:

Yrr Mørch, CTO and Co-founder yrr.morch@naden.com +47 402 34 744

Annbjørg Falck, CEO and Co-founder